Clinical Trial: SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer

U.S., Dec. 2 -- ClinicalTrials.gov registry received information related to the study (NCT07256236) titled 'SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer' on Nov. 20.

Brief Summary: This study is a prospective, single arm II clinical trial. The main objective of the study is to evaluate the efficacy and safety of the combination of Sacituzumab Tirumotecan (SKB264) and QL1706 in the treatment of recurrent or metastatic cervical cancer.

Study Start Date: Dec. 15

Study Type: INTERVENTIONAL

Condition: Cervical Cancer

Intervention: DRUG: Sacituzumab tirumotecan

intravenous (IV) infusion (4mg/kg, Q2W)

DRUG: QL1706

intravenous (IV) infusion (3mg/kg, Q2W). Continuous administration will be maintained until radiological dis...